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Anthrax is a zoonotic disease caused by Bacillus anthracis spore-forming bacterium.
Since it is primarily a disease of animals, the control in animals, and humans depend
on the prevention in livestock, principally cattle, sheep, and goats. Most veterinary
vaccines utilize the toxigenic, uncapsulated (pXO1+/pXO2–) B. anthracis strain 34F2
which affords protection through the production of neutralizing antibodies directed to the
toxin components Protective Antigen (PA), Lethal Factor (LF), and Edema Factor (EF).
The titration of specific antibodies in sera of vaccinated animals is crucial to evaluate
the efficacy of the vaccination and to obtain epidemiological information for an effective
anthrax surveillance. In this study, we developed a Sterne-based Complement Fixation
Test (CFT) to detect specific antibodies induced in animals vaccinated with Sterne 34F2.
We assessed its efficacy in laboratory animals and under field conditions by monitoring
the humoral response induced by vaccination in cattle. The results indicated that the
Sterne-based CFT is able to correctly identify vaccinated animals. It proved to be a very
sensitive and specific test. Moreover, the Sterne-based CFT offers many benefits with
regard to costs, standardization and reproducibility of the assay procedure.
Keywords: anthrax, serology, complement fixation test, antibody response, vaccination
INTRODUCTION
Anthrax Q6is
Q7
a zoonotic disease with an almost worldwide distribution, with prevalence in tropical
and sub-tropical countries (Biswas et al., 2011). The causative agent is Bacillus anthracis, a Gram-
positive, aerobic, spore-forming bacterium. It is primarily a disease of herbivores; ruminants such
as cattle, goats, and sheep are the most susceptible animals (World Health Organization [WHO],
2008). Animals become infected thorough contact with soil contaminated with persistent bacterial
spores. Humans are susceptible to infection through contact with infected animals or animal
products contaminated with anthrax spores. Depending of the route of the exposure, human
anthrax infection can take three forms: cutaneous, gastro-intestinal, and inhalational anthrax. The
majority of reported cases are cutaneous (95%), especially in developing countries whose main
source of income is farming (Ghosh and Goel, 2012).
Bacillus anthracis has two principal virulence factors, the toxin complex, and the poly-
γ-D-glutamic acid capsule, coded by plasmids pXO1 and pXO2, respectively. The capsule
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protects the bacterium from phagocytosis while the toxin
complex consists of three synergistically acting proteins,
Protective Antigen (PA), Lethal Factor (LF), and Edema Factor
(EF), produced during the log phase of growth. The interaction
of these proteins forms the lethal and edema toxins, responsible
for cytotoxic effects (Collier and Young, 2003; World Health
Organization [WHO], 2008). The protection against anthrax
mainly depends on the host’s humoral response to the toxin
components (Turnbull et al., 1988; Pitt et al., 2001; Friedlander
et al., 2002). The PA is a key element: the anti-PA antibodies are
not, in themselves, a guarantee of protected status, but they must
be in the blood of animal or human for the subject to be protected
(Ivins and Welkos, 1988; Ivins et al., 1990; Little et al., 1997).
Since anthrax is primarily a disease of animals, its control
in animals and humans depends on the prevention in livestock,
principally cattle, sheep, and goats. Most anthrax vaccines
for animals utilize the B. anthracis strain 34F2, developed
by Max Sterne in 1937 (Sterne, 1939) which lacks genes for
capsule formation but still produces the toxin (pXO1+/pXO2–),
responsible for the induction of protective antibodies. The
protective effect of a single dose of this vaccine is said to last for
9 to 12 months so annual boosters are recommended in endemic
areas (Sterne, 1939). Also, a single dose of Sterne vaccine may not
be sufficient to ensure protective immunity in the animal to last
for a year, and more than one initial dose of the Sterne vaccine
may be necessary (Turnbull et al., 2004; Mongoh et al., 2008;
World Health Organization [WHO], 2008). However, very few
studies focusing on immunological characterization have been
conducted with cattle and goats (Dipti et al., 2013; Roy et al.,
2013).
Serological methods, which have not a prominent role in
diagnosis, are very useful epidemiological and research tools
(Turnbull et al., 1992; Quinn et al., 2004) since they enable to
monitor the humoral response following vaccination or naturally
acquired infection. The titration of specific antibodies in sera
of vaccinated animals is crucial to evaluate the efficacy of the
vaccination and to obtain epidemiological information in areas
where the disease is endemic.
Currently, the ELISA is considered the most effective
serological method; however, it utilizes purified toxin antigens
PA and LF whose preparation is expensive and lacks of a good
standardization in regard to purity, composition of antigens and
preparation procedure. Moreover, reference standard serum is
not available.
The Complement Fixation Test (CFT) is a serological
method prescribed as individual confirmatory test in many
infectious diseases. It is able to detect specific antibodies in
animal and human serum samples and may detect incomplete
antibodies. The antigen preparation, mainly consisting in an
inactivated bacterial suspension, is not expensive and can be
easily standardized.
The purpose of this study was to develop a Sterne-based
CFT able to detect anti-anthrax antibodies induced in animals
vaccinated with the Sterne 34F2 vaccine. We assessed the efficacy
of our method in laboratory animals and under field conditions
by monitoring the humoral response induced in cattle by
vaccination with Sterne 34F2.
MATERIALS AND METHODS
Bacterial Strains and Growth Conditions
The B. anthracis strain 34F2, used for the preparation of the
veterinary vaccine, and the virulent strain B. anthracis A0843
(Fasanella et al., 2001) were supplied by the National Reference
Centre for Anthrax (Ce.R.N.A.) of the Istituto Zooprofilattico
Sperimentale of Puglia and Basilicata (Foggia, Italy). This
Institute is charged with the production of the Sterne 34F2
vaccine, routinely used for immunization of susceptible animal
species in Italy (Italian DM 7-7-1992). Both strains were cultured
at 37◦C on agar tryptose soy agar supplemented with 5% of
equine serum (TSA/S).
Animals
In this study the ability of the Sterne-based CFT to detect the
antibody response induced by vaccination with Sterne 34F2 was
evaluated in rabbits and cattle.
New Zealand White (NZW) rabbits, weighting 1.2–1.5 kg,
provided by Harlan Laboratories srl (Udine, Italy) were
individually housed in barrier housing with filtered inflow air in
a restricted-access room and under pathogen-limited conditions.
Experiments were conducted in accordance with the current
European Legislation (Directive 86/609/EEC) relating the welfare
of animals involved in experiments.
Breed Limousine female cattle, 10–12 months of age,
belonging to a farm in Basilicata, a southern region of Italy where
anthrax is enzootic, were used.
Experimental Design
Thirty-eight NZW rabbits were vaccinated subcutaneously (s.c.)
two times, at 15 days interval, with 1 ml/each containing
1.2 × 107 live spores of Sterne 34F2 vaccine. Blood samples were
collected from all rabbits prior to vaccination (day 0), 15 days
after the first vaccination (15 days post-vaccination, dpv) and
15 days after the second vaccination (30 dpv). Nine unvaccinated
rabbits were kept as controls.
On the same day of the last sampling, all rabbits, vaccinated
and controls were challenged with 200LD50 of B. anthracis
virulent strain A0843 to evaluate the protective activity of the
vaccine.
Forty-six female cattle were vaccinated subcutaneously with
1 ml/each containing 1.2× 107 live spores of Sterne 34F2 vaccine,
as prescribed by the Italian DM 7-7-1992. Ten, unvaccinated
female cattle belonging to the same farm were kept as controls.
Blood samples were collected prior vaccination (day 0) and
then at 12, 30, and 150 dpv.
After incubation at 37◦C for 30 min to clot, serum samples
were collected by centrifugation and stored at –20◦C until use.
All sera were tested by the Sterne-based CFT.
Complement Fixation Test: Principle of
the Method
The CFT consists of two stages: in the first stage, specific antigen
and test serum are mixed with guinea-pig serum which contains
the complement. If specific antibodies are present in the test
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serum, the complement combines with the antigen–antibody
complex and cannot react in the second stage of the reaction.
In the second stage, sheep erythrocytes previously sensitized
with rabbit serum anti-sheep erythrocytes (hemolytic system), are
added. If the complement has been fixed in the first stage, no
hemolysis will occur (positive reaction). On the contrary, if the
serum test doesn’t contain specific antibodies, the complement,
not consumed, can combine with the hemolytic system causing
the lysis of sheep erythrocytes (negative reaction).
The CFT required the following reagents: (i) lyophilized
guinea-pig complement (serum of healthy guinea pigs); (ii)
hemolysin stock solution (monoclonal antibodies against sheep
erythrocytes), (iii) sheep erythrocytes (54 × 107 cells/ml); (iv)
bovine, hyperimmune serum containing anti-anthrax antibodies
(positive control); (v) pool of sera from healthy, unvaccinated
cattle (negative control).
For this study, sheep erythrocytes, hemolysin, and
complement were supplied by Emozoo Snc of Ripabelli G.
& C. (Siena, Italy). Positive and negative controls, previously
evaluated by ELISA (Fasanella et al., 2006), were provided by the
Ce.R.N.A.
The Veronal calcium–magnesium buffer, pH 7.2± 0.1 (Lonza,
Walkersville, Inc., USA), added with 0.1% of bovine serum
albumin (VBA), was used as diluent.
Sterne Antigen Preparation and Titration
for Use in CFT
The Sterne antigen for CFT was prepared as follows: single
colonies of B. anthracis strain 34F2 were cultured for 24 h at 37◦C
on TSA/S plates and then on Roux flasks for propagation. After
incubation, bacteria were harvested with physiological saline (pH
7.2), inspected for purity by Gram staining and washed twice
by centrifugation at 1.430 g for 15 min. For the inactivation,
the bacterial suspension was added with 3% of formalin saline
and incubated overnight at 37◦C. After inactivation checking, the
suspension was centrifuged as above and the pellet was suspended
in 0.5% of formalin saline for storage until use.
For use in the CFT, the Sterne antigen was titrated as
prescribed by the OIE Manual of Diagnostic Tests for diagnosis
of brucellosis (Office International des Epizooties [OIE], 2008).
Briefly, doubling dilutions of the antigen, each supplemented
with 5% of Fetal Calf Serum (FCS, OXOID), were tested in CFT
to establish the optimal concentration which was able to: (i) react
positively with the positive control; (ii) do not react with the
negative control; (iii) do not show anticomplementary activity.
The anticomplementary activity occurs when the antigen fixes the
complement in absence of the antigen-antibody complex, thus
giving false positive reactions.
The optical density of the optimal antigen concentration,
measured at 490 nm, gave a value of 0.2.
Sterne-Based CFT on Rabbit and Bovine
Serum Samples
Before the CFT, all sera were diluted 1:2 in VBA and incubated
for 30 min at the appropriate temperature to inactivate the native
complement (58◦C for cattle, 62◦C for rabbits). The Sterne-
based CFT was performed as previously described (Adone and
Ciuchini, 1999; Adone et al., 2008). Briefly, in 96-well round-
bottom plates 25 µl of each serum was serially diluted in
VBA from 1:2 to 1:128. Then, 25 µl of antigen and 25 µl of
complement, at working dilution, were added and plates were
incubated at 37◦C for 30 min. After incubation, 25µl of sensitized
erythrocytes were added to each well. After incubation as above,
plates were centrifuged at 200 g for 5 min to allow any unlysated
cells to deposit and the reaction was read over a diffused white
light. The results were evaluated as follows: 100% hemolysis
was considered as negative reaction while all reactions showing
complete absence of hemolysis (0%) or partial hemolysis 75, 50,
or 25% were considered as positive. The titer of each serum was
the highest dilution showing a positive reaction. Based on our
previous experience (unpublished data), the serum dilution 1:2
showing 50% of hemolysis was taken as the reactivity threshold
of the reaction.
Sensitivity (SN) and Specificity (SP) of
the Sterne-Based CFT
The SN and SP of the Sterne-based CFT were determined, at
different times, by categorizing the results into reactive and non-
reactive by application of the reactivity threshold (titer 1:2).
The SP of the assay was calculated as TN/(TN+FP), where
TN= true negatives and FP= false positives. The SN of the assay
was calculated as TP/(TP+FN), where TP = true positives and
FN= false negatives.
Sterne-vaccinated animals were considered as true positives,
while unvaccinated controls and animals bled prior vaccination
were considered as true negatives.
Statistical Analysis
Different percentage of serology performed at different time
points was calculated by using Contingency tables for non-
parametric data (Fisher’s exact test). Results were considered
significant at p ≤ 0.05.
RESULTS
Rabbit Sera CFT Titers
The results of the Sterne-based CFT performed on sera collected
from 38 NZW rabbits vaccinated with Sterne 34F2 (1.2 × 107
live spores /each), are showed in Figure 1. As shown, none of
serum samples from rabbits bled prior vaccination (dpv 0) and
from nine unvaccinated controls gave positive results. At 15 days
after the first vaccination (15 dpv), 89% (34/38) of rabbits weakly
reacted in CFT, titers ranging from 1:2 (15/38), considered as the
reactivity threshold of the reaction, to 1:8 (1/38). The majority
of them, (18/38), gave a titer of 1:4. In contrast, at 15 days
after the second vaccination (30 dpv), all rabbits (38/38) were
seropositive with titers ranging from 1:4 (2/38) to 1:64 (4/38),
with a prevalence of titer 1:16 (18/38). Five rabbits (5/38) titrated
1:8, and nine rabbits (9/38) gave a titer 1:32. All CFT titers
were significantly over the reactivity threshold (Fisher’s exact test
p< 0.01).
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FIGURE 1 | DistributionQ4 of
Q5
CFT titers of thirty-eight NZW rabbits vaccinated with 1.2 × 107 live spores of Sterne 34F2/each, measured by
Sterne-based CFT prior to vaccination (dpv 0), at 15 and 30 days post vaccination. At 15 dpv, rabbits received the second dose of vaccine. Black and white
circles represent the vaccinated and unvaccinated (controls) rabbits, respectively. The broken line indicates the reactivity threshold of the reaction (titer 1:2).
All seropositive rabbits survived to the challenge with the
virulent strain while all controls died (data not shown).
Bovine Sera CFT Titers
The results of the Sterne-based CFT performed on sera collected
from 46 cattle vaccinated with Sterne 34F2 (1.2 × 107 live
spores /each), are presented in Figure 2. As shown, none of
cattle bled prior to vaccination (dpv 0) or unvaccinated controls
were seropositive, thus indicating 100% of specificity. At 12 days
post vaccination, complement fixating antibodies to Sterne were
detected in 72% of calves (33/46), titers ranging from 1:4 (16/46)
to 1:32 (1/46). Eight cattle (8/46) gave a titer 1:8 and the
remaining eight cattle (8/46) gave a titer 1:16. At 30 dpv, all cattle
(46/46) were seropositive, titers significantly increasing from 1:16
(1/46) to 1:128 (1/46). Most of them (31/46) gave a titer 1:32,
while 13/46 titrated 1:64. All CFT titers were significantly over
the reactivity threshold. At 150 dpv, only 13% (6/46) of calves
were still seropositive (Fisher’s exact test p= 0.02) with decreased
titers from 1:4 (3/46) to 1:16 (1/46). Two cattle (2/46) titrated 1:8.
Six cattle (6/46) gave a titer 1:2 corresponding to the reactivity
threshold of the reaction.
Kinetic of the Antibody Response
Induced by Vaccination in Cattle
As shown in Figure 2, at 12 days post vaccination, detectable
antibodies to Sterne were present in 72% of cattle (33/46). At
30 dpv, 100% of cattle were seropositive, showing high and similar
antibody titers to Sterne antigen. At 150 dpv, specific antibodies
to Sterne were detected only in 13% of cattle.
DISCUSSION
The protective activity of anthrax vaccines mainly depends on
their ability to elicit antibodies directed to toxin components
(Little et al., 1997; Beedham et al., 2001; Reuveny et al., 2001;
Kobiler et al., 2002); however, little is known on the effective
duration of immunity, many studies demonstrating the decline
of the specific antibody response and the need of different
vaccination schedules to ensure protection. New, improved
livestock vaccines should be developed able to induce high level
of protective antibodies in a very short time and that could
be administered with long-acting antibiotics during the anthrax
outbreaks or in emergency (Welkos et al., 2001; Fasanella et al.,
2008; World Health Organization [WHO], 2008).
For humans, licensed vaccines are composed by killed, cell-
free suspensions, to avoid the risks due to the residual virulence of
live strains. They are targeted at persons occupationally exposed
to anthrax spores or involved in occupations related to defense.
In contrast, most veterinary vaccines are composed by live
spores of attenuated (non-capsulated) B. anthracis strain 34F2
(Sterne, 1939) suspended in saponin for enhancing immune
response. The non-capsulated variants of B. anthracis may lose
their immunogenicity when cultured, so their efficiency must be
monitored (Sterne, 1939, 1959).
Serological tests, which have not a great diagnostic value,
proved to be a very useful epidemiological and research tool to
evaluate the seroconversion following vaccination or naturally
acquired infection (Turnbull et al., 1992; Quinn et al., 2004).
Demonstration of specific antibodies in sera of vaccinated
animals is needed to obtain epidemiological information in
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FIGURE 2 | Distribution of CFT titers of forty-six cattle vaccinated with 1.2 × 107 live spores of Sterne 34F2/each, measured by Sterne-based CFT
prior to vaccination (dpv 0) and at 12, 30, and 150 dpv. Black and white circles represent the vaccinated and unvaccinated (controls) cattle, respectively. The
broken line indicates the reactivity threshold of the reaction (titer 1:2).
areas where the disease is endemic and to evaluate the efficacy
of the vaccination. In effect, there is still a general paucity
of information related to the onset, kinetic, and magnitude
of antibody response induced by vaccination in humans and
animals.
Effective serological tests should be satisfactory in terms of
sensitivity and specificity, not expensive, to avoid that their use is
confined to a few specialist laboratories, and easy to standardize.
In this study, we assessed the suitability of a Sterne-based CFT
as method for the detection of specific antibodies in laboratory
and target animals vaccinated with Sterne 34F2. We evaluated its
specificity and sensitivity by testing unvaccinated and vaccinated
animals, respectively, at different sampling times.
We prepared and titratedQ10 an inactivated Sterne suspension for
use as antigen in CFT according to OIE indications and our CFT
experience (Adone and Ciuchini, 1999; Adone et al., 2008). The
addition of FCS increases the sensitivity of the reaction, reducing
the number of false negative results asQ11 previously suggested (Cho,
1971).
The humoral response in NZW rabbits vaccinated with Sterne
34F2 was evaluated according to the procedure used by Ce.R.N.A.
to measure the potency of anthrax vaccines. For this purpose,
rabbits were vaccinated twice, 15 days apart, with 1.2 × 107 live
spores of Sterne 34F2 and 15 days after the second vaccination all
rabbits, vaccinated and controls, were challenged with 200LD50
of the virulent strain B. anthracis A0843. The antibody response
was monitored prior to vaccination, 15 days after the first
vaccination, and 15 days after the second vaccination, on the
same day of the challenge. As shown in Figure 1, the Sterne-
based CFT was able to detect all vaccinated rabbits at 30 dpv,
15 days after the second vaccination. Most of seropositive rabbits
gave complement fixating titers ranging from 1:16 to 1:32 thus
significantly over the reactivity threshold. All seropositive rabbits
survived to the challenge with the virulent strain while all controls
died (data not shown) indicating that the humoral response
measured by the Sterne-based CFT was protective. None of
serum samples collected from rabbits prior vaccination or from
unvaccinated controls gave positive results, thus indicating 100%
of specificity (Figure 1).
Data obtained in rabbits indicated that a correlation
between the complement fixating titers to Sterne and the
protective activity afforded by the vaccine may be experimentally
established. Based on our results, rabbits showing detectable
complement fixating antibodies with titers significantly over the
threshold of 1:2 were protected against anthrax infection.
Additional tests are in progress in our laboratory to
confirm the suitability of the Sterne-based CFT as tool
to measure the potency of anthrax vaccines in laboratory
animals by evaluating antibody response in replacement of
the challenge with virulent strains. The availability of methods
alternative to experimental infection could avoid the need
of containment equipment and facilities required to reduce
the risks for personnel exposed to biosafety level 3 agents
(Little et al., 2004). Moreover, it could minimize animal
suffering, in agreement with principles for more ethical use of
animals.
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In cattle, the Sterne-based CFT was able to detect vaccinated
animals with a sensitivity ranging from 72% at 12 dpv to
100% one month after the vaccination (Figure 2). At this time,
complement fixating titers ranged from 1:16 to 1:128 with a
prevalence of titer 1:32 thus significantly over the reactivity
threshold. At 150 dpv, only 13% of cattle were still seropositive,
showing weak CFT titers. None of cattle bled prior vaccination
or unvaccinated cattle gave positive results, thus confirming the
high specificity of this test (Figure 2).
To evaluate the ability of the Sterne-based CFT to detect
antibodies in other species, we tested serum samples from Sterne-
vaccinated sheep, goats and horses: all vaccinated animals were
identified, while proven uninfected or unvaccinated animals did
not react (data not shown). Continuing validation is ongoing as
samples with proven status and provenance become available.
As a serological method, the Sterne-based CFT could offer
many benefits: (i) the reagents are not expensive and may be
easily standardized: the optimal concentration of the antigen
may be accurately determined and standardized. The other
reagents are titrated according to classical procedures described
by the OIE; (ii) the preparation of the antigen does not require
particular growth conditions or safety measures since risks
to personnel manipulating the Sterne 34F2 are not greater
than those posed by other category 2 organisms (Centers for
Diseases Control Prevention, Division of Foodborne, Bacterial
Mycotic Diseases); (iii) high-quality samples are not required, the
anticomplementary reactions occurring rarely; (iv) the CFT is not
animal species-specific: the same reagents are used to test sera
from a variety of animal species and humans.
We did not test serum samples from anthrax-vaccinated
people: however, since the procedure for detection of animal
antibodies are identical to those used for human antibodies, we
think that the Sterne-based CFT could be a useful research tool
to evaluate the immunogenicity of anthrax vaccines in humans.
This methodology, if officially accepted, could replace the lethal
challenge with virulent anthrax strain, which is an expensive and
increasingly unacceptable test.
The Sterne-based CFT could be particularly useful in
veterinary medicine since serological tests are mostly involved in
testing of herds or flocks of animals rather than single animals;
the analysis of serological data should indicate whether the
herd/flock is infected/vaccinated or not to obtain epidemiological
information.
The CFT results indicated that the production of specific
antibodies induced by vaccination with Sterne 34F2 did not
persist over a long period of time in cattle. In many studies,
conducted in cattle and goats, the antibody response following
vaccination against anthrax was monitored using a PA-based
ELISA, currently accepted as the best serological procedure, and
different antibody kinetics were observed (Dipti et al., 2013; Roy
et al., 2013; Hassan et al., 2015). However, the comparison of
serological data is very difficult since many factors affect the
immune response of animals, such as the vaccine type, the age
of vaccination and, mostly, the health status of animals (IOWA
Beef Center website, 2015).
The importance of antibody kinetics in relation to the
vaccine efficacy has been well demonstrated; it is a crucial
information that should be taken in consideration for the
implementation of effective prevention and control measures to
protect population, also considering that B. anthracis is one of the
preferred pathogenic agents for use as bacteriological weapon in
bioterrorism attacks (Inglesby et al., 1999).
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